Evidence map›Paper›PMID 22022421›Full record

ArticlePloS one2011

A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases.

Hamid Moha ou Maati, Rémi Peyronnet, Christelle Devader, Julie Veyssiere, Fabien Labbal, Carine Gandin, Jean Mazella, Catherine Heurteaux, Marc Borsotto

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Simultaneous assessment of radial and axial myocyte mechanics by combining atomic force microscopy and carbon fibre techniques.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The role of K₂p channels in anaesthesia and sleep.Pflugers Archiv : European journal of physiology · 2015
    Review
  16. Article
  17. Article
  18. TREK-king the blood-brain-barrier.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2014
    Review
  19. Article
  20. Molecular candidates for cardiac stretch-activated ion channels.Global cardiology science & practice · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hamid Moha ou MaatiInstitut de Pharmacologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique (UMR6097), Université de Nice Sophia Antipolis, Valbonne, France.
Rémi Peyronnet
Christelle Devader
Julie Veyssiere
Fabien Labbal
Carine Gandin
Jean Mazella
Catherine Heurteaux
Marc Borsotto
Centre National de la Recherche Scientifique · FRInstitut de Pharmacologie Moléculaire et Cellulaire · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TREK-1 potassium channels are involved in a number of physiopathological processes such as neuroprotection, pain and depression. Molecules able to open or to block these channels can be clinically important. Having a cell model for screening such molecules is of particular interest. Here, we describe the development of the first available cell line that constituvely expresses the TREK-1 channel. The TREK-1 channel expressed by the h-TREK-1/HEK cell line has conserved all its modulation properties. It is opened by stretch, pH, polyunsaturated fatty acids and by the neuroprotective molecule, riluzole and it is blocked by spadin or fluoxetine. We also demonstrate that the h-TREK-1/HEK cell line is protected against ischemia by using the oxygen-glucose deprivation model.

Indexed as

Cell HypoxiaDrug DiscoveryDrug Evaluation, PreclinicalFatty Acids, UnsaturatedFluoxetineGreen Fluorescent ProteinsHEK293 CellsHumansHydrogen-Ion ConcentrationIon Channel GatingNervous System DiseasesNeuroprotective AgentsPatch-Clamp TechniquesPeptidesPotassium Channels, Tandem Pore DomainProtein TransportFatty Acids, UnsaturatedFluoxetineGreen Fluorescent ProteinsNeuroprotective AgentsPeptidespotassium channel protein TREK-1Potassium Channels, Tandem Pore DomainReceptors, Cell SurfaceRiluzolespadin peptide

Identifiers

PMID22022421
PMCPMC3194802
OpenAlexW1963609397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.